Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients

Trial ID #	Letrozole University Hospital Basel
Phase	Single-site
Drug Class	Hormonal Therapy: Aromatase
Drug Name	Letrozole
Alternate Drug Names	Femara
Drugs in Trial	Letrozole
Eligible Participant	High grade serous, stage III/IV, ER-positive patients after surgery and first-line adjuvant platinum-based therapy
Patients Enrolled	50
Therapy Setting	Maintenance
Study Design	Open-Label, Non-randomized
Endpoints	RFS, evaluated per RECIST
Biomarkers	ER protein
Efficacy	Let maint vs Placebo, at 24 months follow-up: All patients: RFS: NR (n=23) vs 13.2 months (n=27, p=0.035) Patients w/o residual disease: RFS: NR (n=16) vs 20.8 months (n=21, p=0.11) Patients w/ residual disease: RFS: 21.6 (n=7) vs 8.8 months (n=6, p=0.026)
Clinically Significant Adverse Events	Serious AE: none Grade 3-4 AE: none Grade 1-2 AE: hot flashes, fatigue, bone pain (6.4%)
Conclusion	Promising activity with minimal toxicity in ER-positive patients
Reference	Heinzelmann-Schwarz et al. Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients. Gynecol Oncol (2018) 148(1):79-85. https://www.ncbi.nlm.nih.gov/pubmed/29157627